共 73 条
- [21] Gilead Sciences I, Sunlenca (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV
- [23] 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2 [J]. LANCET HIV, 2018, 5 (07): : E390 - E399
- [24] Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis [J]. HELIYON, 2018, 4 (12):
- [29] Highly accurate protein structure prediction with AlphaFold [J]. NATURE, 2021, 596 (7873) : 583 - +